Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jul 8 2015Immune Pharmaceuticals Inc.

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. Endo will pay undisclosed milestones to Immune if Endo receives a back pain indication for a lidocaine-based product, as per the original 2003 Licensing Agreement.

Immune will re-gain full exclusive rights to develop, commercialize and license LidoPain®, a high-dose lidocaine patch for the treatment of acute pain. LidoPain® is currently in Phase II clinical development.

Source:

Immune Pharmaceuticals Inc.

Posted in: Business / Finance | Medical Patent News | Pharmaceutical News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Research finds link between unhealthy eating and chronic pain severity, calls for comprehensive dietary support
Pain reliever use in pregnancy shows no link to child neurodevelopmental disorders, study finds
Examining how pain could play a direct protective role in the gut
Caffeine vs. creatine: The impact on cognitive and physical performances
Beetroot juice outperforms nitrate supplements in boosting exercise performance
Research finds link between unhealthy eating and chronic pain severity, calls for comprehensive dietary support
Childhood trauma linked to higher rates of somatic symptoms, study finds
Study reveals nerve changes linked to pain and urinary frequency in recurrent UTI sufferers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Depression linked to chronic pain: Variability shown across patient characteristics